{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T03:19:45Z","timestamp":1790824785151,"version":"4.1.0"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2016,6,14]],"date-time":"2016-06-14T00:00:00Z","timestamp":1465862400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"National Cancer Institute (US)","award":["P50CA097186"],"award-info":[{"award-number":["P50CA097186"]}]},{"name":"Prostate Cancer Foundation (US)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1007\/s12032-016-0793-1","type":"journal-article","created":{"date-parts":[[2016,6,14]],"date-time":"2016-06-14T08:56:59Z","timestamp":1465894619000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Docetaxel-related toxicity in metastatic hormone-sensitive and metastatic castration-resistant prostate cancer"],"prefix":"10.1007","volume":"33","author":[{"given":"Michael T.","family":"Schweizer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"Gulati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elahe A.","family":"Mostaghel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter S.","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Bruce","family":"Montgomery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan Y.","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather H.","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,6,14]]},"reference":[{"issue":"15","key":"793_CR1","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1056\/NEJMoa041318","volume":"351","author":"DP Petrylak","year":"2004","unstructured":"Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351(15):1513\u201320. doi: 10.1056\/NEJMoa041318 .","journal-title":"N Engl J Med"},{"issue":"15","key":"793_CR2","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1056\/NEJMoa040720","volume":"351","author":"IF Tannock","year":"2004","unstructured":"Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351(15):1502\u201312. doi: 10.1056\/NEJMoa040720 .","journal-title":"N Engl J Med"},{"issue":"2","key":"793_CR3","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/s1470-2045(12)70560-0","volume":"14","author":"G Gravis","year":"2013","unstructured":"Gravis G, Fizazi K, Joly F, Oudard S, Priou F, Esterni B, et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013;14(2):149\u201358. doi: 10.1016\/s1470-2045(12)70560-0 .","journal-title":"Lancet Oncol"},{"key":"793_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(15)01037-5","author":"ND James","year":"2015","unstructured":"James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2015. doi: 10.1016\/s0140-6736(15)01037-5 .","journal-title":"Lancet"},{"issue":"8","key":"793_CR5","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1056\/NEJMoa1503747","volume":"373","author":"CJ Sweeney","year":"2015","unstructured":"Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015;373(8):737\u201346. doi: 10.1056\/NEJMoa1503747 .","journal-title":"N Engl J Med"},{"issue":"2","key":"793_CR6","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/s1470-2045(12)70591-0","volume":"14","author":"C Sweeney","year":"2013","unstructured":"Sweeney C. Prostate cancer therapy: going forwards by going backwards. Lancet Oncol. 2013;14(2):104\u20135. doi: 10.1016\/s1470-2045(12)70591-0 .","journal-title":"Lancet Oncol"},{"key":"793_CR7","unstructured":"National Institutes of Health (NIH). NIH-funded study shows increased survival in men with metastatic prostate cancer who receive chemotherapy when starting hormone therapy. 2013. http:\/\/www.nih.gov\/news-events\/news-releases\/nih-funded-study-shows-increased-survival-men-metastatic-prostate-cancer-who-receive-chemotherapy-when-starting-hormone-therapy . Accessed 24 Mar 2016."},{"issue":"11","key":"793_CR8","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.6004\/jnccn.2012.0146","volume":"10","author":"LR Baden","year":"2012","unstructured":"Baden LR, Bensinger W, Angarone M, Casper C, Dubberke ER, Freifeld AG, et al. Prevention and treatment of cancer-related infections. J Natl Compr Canc Netw JNCCN. 2012;10(11):1412\u201345.","journal-title":"J Natl Compr Canc Netw JNCCN"},{"issue":"28","key":"793_CR9","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.1200\/jco.2015.62.3488","volume":"33","author":"TJ Smith","year":"2015","unstructured":"Smith TJ, Bohlke K, Lyman GH, Carson KR, Crawford J, Cross SJ, et al. Recommendations for the use of WBC growth factors: american society of clinical oncology clinical practice guideline update. J Clin Oncol Off J Am Soc Clin Oncol. 2015;33(28):3199\u2013212. doi: 10.1200\/jco.2015.62.3488 .","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"30","key":"793_CR10","doi-asserted-by":"publisher","first-page":"4562","DOI":"10.1200\/jco.2010.30.7025","volume":"28","author":"RM Franke","year":"2010","unstructured":"Franke RM, Carducci MA, Rudek MA, Baker SD, Sparreboom A. Castration-dependent pharmacokinetics of docetaxel in patients with prostate cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28(30):4562\u20137. doi: 10.1200\/jco.2010.30.7025 .","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"11","key":"793_CR11","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1111\/j.1464-410X.2008.08183.x","volume":"102","author":"L Klotz","year":"2008","unstructured":"Klotz L, Boccon-Gibod L, Shore ND, Andreou C, Persson BE, Cantor P, et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int. 2008;102(11):1531\u20138. doi: 10.1111\/j.1464-410X.2008.08183.x .","journal-title":"BJU Int"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-016-0793-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12032-016-0793-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-016-0793-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T16:20:09Z","timestamp":1498321209000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12032-016-0793-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,14]]},"references-count":11,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["793"],"URL":"https:\/\/doi.org\/10.1007\/s12032-016-0793-1","relation":{},"ISSN":["1357-0560","1559-131X"],"issn-type":[{"value":"1357-0560","type":"print"},{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,14]]},"article-number":"77"}}